The Canadian Originator Biologics Coalition (COBC) is a newly formed group uniting pharmaceutical companies dedicated to the development of innovative biologic medicines.

Our members currently include AbbVie Corporation, Janssen Inc. and Takeda Canada Inc.

We believe the approval of new treatment options, including biosimilars, is a positive development for patients and the Canadian healthcare system.

Our goal is to foster an environment that supports both innovation and health system sustainability -- a system where biosimilars and originator biologic medicines can co-exist for the benefit of patients and the Canadian healthcare system.


Biologic drugs come from living organisms or from their cells, and are often made using biotechnology. They are used to treat diseases and medical conditions including anemia, diabetes, inflammatory bowel disease, psoriasis, rheumatoid arthritis, hormone deficiency and some forms of cancer. Biologic drugs are generally larger and more complex than chemically produced pharmaceutical drugs.1

Biosimilars are drugs demonstrated to be highly similar to biologic drugs that were already authorized for sale (known as the reference biologic drug). Biosimilars were previously known in Canada as Subsequent Entry Biologics (SEBs). Biosimilars are approved based on a thorough comparison to a reference drug and may enter the market after the expiry of reference drug patents and data protection.2

For more information, click here to read our white paper.